

1 **Impact of health systems interventions in primary health**
2 **settings on type 2 diabetes care and health outcomes**
3 **among adults in West Africa: a systematic review protocol**

4

5

6 Eugene Paa Kofi Bondzie^{1*}, Yasmin Jahan^{2¶}, Dina Balabanova^{2¶}, Tony Danso-Appiah⁴, Tolib Mirzoev^{2&},

7 Edward Antwi³, Irene Ayepong^{1&}

8

9

10 ¹Ghana College of Physicians and Surgeons, Accra, Ghana

11 ²London School of Hygiene and Tropical Medicine, London, United Kingdom

12 ³Ghana Health Service, Accra, Ghana

13 ⁴University of Ghana, Legon, Ghana

14

15

16 *Corresponding Author

17 Email: eugenebondzie@gmail.com (EPKB)

18

19

20 [¶]These authors contributed equally to this work

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

21 &These authors also contributed equally to this work

22

23

24 **Funding**

25 This research was conducted as part of the health research on strengthening of capacity for non-
26 communicable diseases (NCD) control in West Africa (Stop NCDs project) commissioned by the
27 National institute for health Research (NIHR), global health research centres: research and
28 institutional capacity strengthening In NCDs Call 1 (grant number- 203246). The views expressed in
29 this publication are those of the author(s) and not necessarily those of the NIHR or the UK
30 government.

31

32

33

34 **Competing interest**

35 None declared

36

37 **Registration details**

38 Prospero registration number is CRD42023439897

39

40

41 **Abstract**

42 Type 2 diabetes remains a major global public health challenge particularly in the African region.
43 Though evidence exists on pharmacological agents and non-pharmacological interventions in
44 maintaining blood glucose concentration, the health systems ability in meeting patients' needs may
45 be inadequate. However, the management of non-communicable diseases particularly diabetes,
46 have been postulated to depend largely on functioning health systems. This systematic review will
47 therefore, summarize the current evidence on existing health systems interventions in primary
48 health settings for type 2 diabetes care and health outcomes in West Africa and would explore the
49 impact of these system-level interventions on service availability, accessibility and quality, as well as
50 individualized outcomes such as glycemic control, disease awareness and treatment adherence.

51 The review will be conducted in accordance with the reporting guidance provided in the Preferred
52 Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P). The health system
53 framework by Witter et al, 2019 will guide the system-level interventions and the search strategy to
54 be explored in this review. This framework was designed to integrate the six building blocks of the
55 World health's organization (WHO) health systems framework and delineates how they work
56 synergistically to improve specific health outcomes. We will search the following databases PubMed,
57 Google scholar and Cumulated Index to Nursing and Allied Health Literature (CINAHL) between
58 January 2000 to June 2023 and Car.info from inception to June 2023. The Cochrane Collaboration
59 tool for assessing Risk of Bias will be implemented on each included study to assess for risk of bias.

60 We will conduct a narrative synthesis and make comparisons across findings using Excel generated
61 tables.

62 The main limitation of this study is that we are likely to miss out on studies not conducted in English
63 or French since our search would be conducted in English and French only.

64 **In Conclusion**, this systematic review will outline the existing system-level interventions that aim to
65 or already improve type 2 diabetes services in primary health facilities in West Africa and would
66 allow for strengthening and co-production of successful interventions that can be generalized to the
67 entire sub-region.

68

69

70 **Introduction**

71 Type 2 diabetes, formerly known as adult-onset diabetes, is a major global public health problem(1).
72 It is defined as a form of diabetes mellitus that is characterized by high blood glucose, insulin
73 resistance and a relative lack of insulin and it manifests with symptoms of increased thirst, frequent
74 urination, weight loss and sometimes increased hunger(2). Long term complications from high blood
75 sugar includes ischemic heart disease, retinopathy, nephropathy and limb amputations(3).
76 Maintaining blood glucose concentration is highly essential to prevent severe complications(4). Until
77 recently, it was thought to affect adults who were middle-aged or older but recent trends have
78 shown an increase incidence in young people(5). Reports from epidemiological studies suggest that
79 adults aged 20-79 years living with type 2 diabetes are about 10.5% of the world's population(6). In
80 Sub-Saharan Africa, the disease is estimated to increase by 129% by 2045 due to an increase in
81 population and rapid urbanization(6). This phenomenon is worsened by the large number of
82 undiagnosed individuals living with the disease. According to published reports from the
83 international diabetes federation (IDF) Atlas, people with undiagnosed diabetes in the African region
84 represent the highest comparative proportions worldwide, currently at 54% and expected to
85 increase by 2045(6). Consequently, the number of diabetes related death was reported at 416,000
86 compared with 111,100 deaths in Europe. These disproportionate number reflect the poor
87 structures at various levels of the primary care management of non-communicable diseases in the

88 African region(7,8). Evidence exists on the effectiveness of pharmacological and non-
89 pharmacological treatment for type 2 diabetes(9,10,11) but the health systems ability in meeting
90 patients' needs may be inadequate(2,7).

91 The management and control of type 2 diabetes is largely dependent on health systems(12). The
92 treatment of diabetes is challenging because health systems are designed for short-term care rather
93 than long-term care of people(13). A healthcare system is an organization of people, institutions,
94 and resources that delivers health care services to meet the health needs of target populations(14).

95 Effective health systems can improve the delivery of diabetes care and promote patient's access and
96 utilization of quality services including access to medications, health facilities and specialists, with an
97 overall impact on glycemic control and other associated outcomes (e.g., adherence, morbidity and
98 mortality etc.)(14,15,16).

99 A previous systematic review was conducted by Nuche-Berenguer, et al (17)on the readiness of
100 health systems in tackling diabetes in Sub-Saharan Africa, with part of the review focused on
101 evaluating pilot projects, targeted at enhancing the capacity of health systems in diabetes care.
102 However, this review was conducted six years ago, at a time when health system interventions
103 towards type 2 diabetes were now evolving in most Sub-Saharan African countries especially West-
104 African countries. Thus, the majority of the studies identified in that review were based-off eastern
105 and southern Africa and the pooled findings may not be necessarily generalizable in recent times to
106 other parts of Africa. The review also could not synthesize the impact of the interventions on
107 glycemic control due to the scarcity of relevant papers.

108 However, studies have been conducted between that period and the present to determine the
109 impact of health system strengthening interventions on glycemic control. These include strategies
110 aimed at improving the training and distribution of healthcare personnel, improving patient follow-
111 up appointments, improving medicines distribution, and decentralizing services to patients at the
112 primary-care level etc. Also, diversity exists between the sub-populations, their economic growth,

113 health facility distribution, general disease burden and political structures. Thus, it will be important
114 to determine which interventions have been practical in the West African sub population.


115 According to the World Health Organization (WHO), health systems interventions can be defined as
116 any array of initiatives that improves one or more of the functions of the health systems and that
117 leads to better health through improvements in access, coverage, quality or efficiency(18). Chee et
118 al, proposed that these initiatives should aim at permanently making the systems function better,
119 not just filling gaps or supporting the systems to produce better short-term outcomes. They further
120 submit that an intervention to strengthen the health system should go beyond providing inputs and
121 apply to more than one building block, citing the six core components of health systems identified by
122 the WHO.

123 For the purposes of this review, the health system interventions framework by Witter et al(18) in
124 2019 would guide the system-level interventions to be explored in this review (S1 Fig). This
125 framework was designed to integrate the six building blocks of the WHO health systems framework
126 (14). The framework by Witter et al, describes mechanisms of change within six health system blocks
127 (governance, financing, infrastructure, workforce, supply chain and information), describes the
128 implementation process goals and outlines the final desired outcomes. Interventions that promote
129 any of these domains of the health system or across integration of the domains, have been proven
130 to have significant impact on the outcome of a health condition (non-communicable disease) in the
131 African setting(19).

132 This systematic review will summarize the recent evidence on health system interventions
133 implemented in primary care facilities to improve the accessibility, delivery and quality of healthcare
134 for type 2 diabetes in West Africa; and will explore the impact and effectiveness of these
135 interventions on overall glycemic control, disease awareness and treatment adherence.

136

137 **S1 Fig. Health systems interventions framework (Modified from the health systems strengthening**
138 **framework by Witter et al(18))**



154

155 **Review question**

156 This systematic review aims to answer the question;

157 How do health systems interventions influence care and health outcomes of type 2 diabetes in
158 primary health settings among adults in West Africa?

159

160 **Objectives**

161 **General**

162 To identify the health system interventions in primary health settings that influence the accessibility,
163 delivery and quality of type 2 diabetes care among adults in West Africa.

164 **Specific**

165 1. To synthesize the evidence on the effectiveness of these system-level interventions on glycemic
166 control, awareness and treatment adherence.

167 2. To explore the impact of these system-level interventions on any associated health outcomes
168 (e.g., service availability, service utilization etc.)

169

170

171 **Methods**

172 This systematic review will follow the reporting guidance provided in the Preferred Reporting Items
173 for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) statement (20) (S1 Checklist)

174

175 **Criteria for considering studies for this review**

176

177 **PICOS eligibility (S1 Table)**

178 **Types of studies**

179 • We will include studies with randomised controlled trials (RCTs) trials, clinical control trials
180 (CCTs) and quasi-experimental designs

181 • Observational studies including cross-sectional studies, cohort studies, case-control studies
182 and case series will be excluded

- 183 • Gray literature (e.g., books, commentary, dissertations, conference proceedings, modeling
184 and simulation studies) will also be excluded.

185 **Types of participants and setting**

- 186 • The participants to be covered in this review will be adults aged 18 years or more in West
187 Africa with a diagnosis of type 2 diabetes.
- 188 • Studies conducted in a primary health facility setting (community health and planning
189 services (CHPS) compound, health center, district hospital/clinic) will be eligible
- 190 • Studies on gestational diabetes (since its natural history varies significantly from type 2
191 diabetes(21)) , and type 1 diabetes will be excluded
- 192 • Also, studies that evaluated both type 1 diabetes and type 2 diabetes together will be
193 excluded, if we cannot extract findings from the group with type 2 diabetes.
- 194 • Studies that explored diabetic care interventions conducted solely in the community setting
195 without describing collaboration with health facilities will be excluded.

196 **Types of Interventions**

197 We will define the health system interventions using the modification from the framework by Witter
198 et al(18) and a descriptive approach employed by Byiringiro et al(19)

- 199 • Studies would be eligible if the interventions address the following health system inputs
200 (i.e., Service delivery, health workforce, supply chain, health information systems, financing
201 governance) in the following ways;
- 202 • Service delivery. WHO defines service delivery as the activities that directly provide safe,
203 effective, and high-quality health services to patients in need. Thus, we will consider the
204 studies to enhance the capacity of this aspect of the health systems if the target of the
205 intervention was to enhance patients access to health services for diabetes like screening,
206 treatment, and follow-up, either through equitable distribution of care services, reduction

207 of out-patient waiting time, revision of time allocated for services, or integrating the
208 delivery of diabetes care with other established health services like HIV or TB.

- 209 • Health workforce. The interventions of interest in this aspect of the health systems would
210 focus on healthcare providers who manage diabetes. The interventions include strategies to
211 increase the number of providers, improve provider knowledge and implementation of
212 diabetes management guidelines, address provider decision support systems, promote
213 teamwork, and institute task sharing and/or task shifting strategies to include providers
214 who do not normally perform certain diabetes management tasks like prescription of
215 medications.
- 216 • Supply chain. In this aspect of the health systems, we will include studies with interventions
217 that target enhancing the capacity of the procurement systems to ensure the availability of
218 anti-diabetic medications, availability and maintenance of calibrated glucometers,
219 availability of consumables to conduct screening and other diabetes investigations, patient
220 follow-up technologies like use of short message systems, and treatment guidelines.
- 221 • Health information systems. We will consider interventions to enhance the capacity of
222 health information systems if they studied an element of the process of patient data
223 collection, analysis, sharing, and use to improve outcomes of interest. Interventions that
224 explore the use of patient registries and information between patients and providers and
225 among providers will be included
- 226 • Financing. The financing aspect of the health systems, as defined in the WHO building
227 blocks, has the most significant relevance on the national macro-level health systems. It
228 also plays an impact on the micro-level health systems' service delivery and patients'
229 outcomes. We will consider studies where the interventions aimed at reducing patients' out
230 of pocket spending or funding of diabetes care at the health facilities through national and
231 sub-national spending on health insurance premiums, or other relevant financial reliefs.

- 232 • Governance. This aspect has direct and indirect associations with the other five building
233 blocks of the health systems. We will consider studies to address leadership and
234 governance if the intervention promote a facility’s leadership awareness of the burden of
235 poor diabetes management, or if the intervention uses strategic planning and
236 implementation of national diabetes management protocols in a health care facility,
237 explores the accountability measures at the health facility, applies regular performance
238 appraisal and planning for improvement, integrates supportive mentorship to lower
239 primary health facilities, institutes a patient feedback collection and response system, or
240 examines the leadership allocation of funds for diabetes management. We will also
241 consider interventions where leadership joins or collaborate with other health facilities or
242 local/international/national/private/non-governmental organizations to manage diabetes.
- 243 • Only studies that piloted interventions with a minimum follow-up period of six months will
244 be eligible.
- 245 • We will exclude studies that examined only patient-level or community-level
246 lifestyle/behavioral changes or other non-conventional medical/non-medical interventions
247 for diabetes management.

248 **Comparison**

249 Intervention groups would be compared with corresponding groups where there were no strategies
250 to enhance any of the health systems inputs with respect to diabetes care.

251 **Outcome**

252 We will evaluate the impact of the interventions on any of the following outcomes:

- 253 • Good glycemic control. Defined by the American college of endocrinologists as glycated
254 hemoglobin (HbA1c %) levels below 7% or fasting blood sugar levels below 110mg/dl (6.1
255 mmol/l)(4).

- 256
- Diabetes awareness. Defined as persons with clinically measured diabetes (either with
- 257 HbA1c or fasting blood sugar levels), who have been diagnosed by a physician or health
- 258 provider with appropriate training to make a diagnosis.
- Treatment Adherence. Defined as consistently complying with a treatment plan (either an
- 259 oral anti-diabetic or insulin, or a life style plan) as prescribed/advised/implemented by a
- 260 health care provider (22).
- Type 2 diabetes service availability and patient’s access to these services
- 262

263 Language

264 We will include articles published in English or French. These two are the main languages spoken in

265 West Africa.

266

267 S1 Table. PICOS eligibility

Population	Adults aged 18 years or more in West Africa
Intervention	System-level interventions that targets the health system inputs in the Witter et al health system frame work within primary health facilities
Comparison	Corresponding groups where there were no strategies to enhance any of the health systems inputs with respect to diabetes care
Outcome	Main outcome is glycaemic control. Other health outcomes include: awareness, treatment adherence, type 2 diabetes services availability and patient access.
Study design	Randomized Controlled Trials (RCTs), Clinical Controlled trials (CCTs), quasi experiments

268

269

270 Search Strategy

271 **Bibliographic databases**

272 We will search the following databases PubMed, Google scholar and Cumulated Index to Nursing
273 and Allied Health Literature (CINAHL) between January 2000 to June 2023 and Car.info from
274 inception to June 2023. This time frame is selected to encompass studies that would have likely
275 benefited from recent development and improvement in RCTs, CCTs and quasi-experimental studies.
276 We will define the search terms for primary health care of diabetes at the facility level by borrowing
277 and modifying the search strategy published in a systematic review of health systems interventions
278 for hypertension by Byiringiro et al(19) These search terms will likely encompass the primary health
279 care practices for diabetes management in our setting of interest.

280 The search strategy consists of intersections between the following medical subject headings
281 (MeSH); ("Health Services," Delivery of Health care," "Primary Health Care," "Health Facilities,"
282 "Health Care Facilities, Manpower, and Services," "Healthcare Financing," "Insurance, Health,
283 Reimbursement, "Health Information Systems," "Equipment and Supplies"); and intersected with
284 type 2 diabetes ("Diabetes mellitus, type 2," "Glycemic Control," "Diabetes Complications,"
285 "Hyperglycemia,") and West African countries ("African, Western"). The full search strategy is
286 presented in S2 Table

287 **Searching other resources**

288 We will check the bibliographies of all relevant studies to identify other potential publications. The
289 references of any relevant systematic reviews and scoping reviews identified will also be scrutinized
290 for relevant trials.

291 We will also contact the authors of articles whose full text is not easily accessible after searching
292 through multiple online databases and where there are questions related to the results of the study
293 or trial design, we will seek confirmation on the information that we extract from their studies. In
294 case of no feedback from the authors, the corresponding studies will be excluded. Also, studies that
295 do not measure any of the outcome variables (glycaemic control, adherence, and awareness) will be

296 excluded. Where there are duplicates for studies published in more than one paper, the most
297 comprehensive one reporting the largest sample size will be considered.

298

299 **Study selection**

300 Two reviewers will independently scan the titles and abstracts of all records yielded by the search to
301 determine their eligibility for full-text screening and their full articles will be assessed through the
302 databases and imported into the [Rayyan](#) screening software(22).

303 The full text of all potentially eligible articles will be screened and assessed for inclusion into the
304 review, by a trained reviewer, using a pre-specified eligibility form based on the inclusion criteria (S3
305 Fig). At least one paper will be piloted before the main selection. Disagreements will be resolved
306 after reaching a consensus or through discussion with a third reviewer. Neither of the review
307 authors will be blind to the authors, institutions or journal titles of potential articles. We will present
308 the number of included studies and the number of excluded studies using the PRISMA flow chart (S3
309 Fig)

310

311 **Data Extraction and management**

312 Two reviewers will independently extract study characteristics and record them on pre-designed
313 forms (S3 Table). The form would first be piloted on two included studies to ensure information is
314 captured in a standard manner. We will extract data from each study on the first author, year of
315 publication, language, study design, setting (country and facility level), health system domain and
316 intervention explored, and outcomes. Disagreements will be resolved in consultation with the third
317 reviewer.

318

319 **Dealing with missing Data**

320 We will contact the authors of included studies for which data related to study methods, and
321 outcomes are unclear or missing.

322

323 **Risk of Bias and quality Assessment of included studies**

324 To assess for possible risk of bias in the included studies, we will collect information using the
325 Cochrane Collaboration tool for assessing Risk of Bias(23)in a study (S4 Fig). The risk of bias tool
326 would be implemented on each study and scored as high, low, or unclear risk (where there is
327 insufficient detail reported), for the following domains: random sequence generation (selection
328 bias); allocation concealment; blinding of participants and personnel (performance bias); blinding of
329 outcome assessment (detection bias); incomplete outcome data (attrition bias); selective reporting
330 (reporting bias). These scores would be assigned independently by the two review authors.
331 Disagreements would be solved by discussion and consultation with a third reviewer. A table
332 representing the risk of bias assessments within and across studies will be computed using
333 Cochrane’s Review Manager (Version 5.3)

334

335 **Data synthesis and Analysis**

336 We will conduct a narrative synthesis of the health system interventions identified from the studies
337 by creating a table to compare the PICO elements. We will classify the outcomes into the following
338 groups; glycemic control, diabetes awareness and treatment adherence. We will use relative risk to
339 report the effect measures of the interventions on diabetes outcomes and compare them across all
340 included studies. Our findings would be reported using tables generated from Excel.

341

342 **Assessment of confidence in cumulative estimate**

343 The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE)(24) approach
344 will be implemented to assess the quality of the evidence for any of the outcomes. We will report a
345 table on the GRADE evidence profile for the quality of the studies on the following domains: 1) risk
346 of bias 2) inconsistency 3) indirectness 4) imprecision 5) publication bias 6) magnitude of effect 7)
347 residual 8) dose-response 9) overall GRADE quality scored as very low (very uncertain about the
348 estimate of effect), low (further research is very likely to change the estimate of effect, moderate
349 (further research may likely change the estimate of effect), high quality (i.e., further research is very
350 unlikely to change our confidence in the estimate of effect). (S5 Fig)

351

352 **Ethical considerations**

353 Ethical approval will not be needed for this review protocol because data will be extracted from
354 published studies and there will be no concerns about privacy.

355

356

357 **Discussion**

358 By the end of this review, we aim to provide a report on integrated system-level interventions in the
359 health systems of primary health facilities aimed at improving the delivery and quality of type 2
360 diabetes services as well as patients access to these services. We will further explore effectiveness of
361 these interventions on the impact on patients' glycemetic control for at least 6 months. We would
362 then outline areas of strengths and gaps in already existing interventions for the purposes of health
363 policies, co-production of interventions and wide-spread uptake in the entire region.

364

365 **Strengths and Limitations**

366 This review will provide valuable insights into the latest health system interventions for the
367 management of type 2 diabetes in West Africa and explore the effect of integrated system-level
368 interventions on provision of care for type 2 diabetes. The literature search would be conducted in
369 only English and French thus we are likely to miss out on relevant studies in other languages. E.g.,
370 Portuguese.

371

372 **Dissemination plans**

373 Results from this review would be disseminated through academic journals, policy briefs, stake
374 holder and intervention co-production workshops.

375

376 **Dealing with Amendments**

377 The corresponding author, Eugene Paa Kofi Bondzie, is responsible for any amendments and update
378 of this review protocol.

379

380

381 **Authors' contributions**

382 **Study protocol conceptualization and design:** Eugene Paa Kofi Bondzie (EPKB), Yasmin Jahan (YJ),
383 Dina Balabanova (DB).

384 **Supervision:** Irene Agyepong (IA), Edward Antwi (ED), Tolib Mirzoev (TM), Tony Danso-Appiah (TDA).

385 **Validation:** Dina Balabanova (DB), Irene Agyepong (IA), Tolib Mirzoev (TM).

386 **Original draft writing:** Eugene Paa Kofi Bondzie (EPKB)

387 **Review and editing:** Eugene Paa Kofi Bondzie (EPKB), Yasmin Jahan (EPKB)

388

389

390 Acknowledgements

391 We would like to acknowledge Mary Poma Agyekum, the librarian who helped in the development
392 of the search strategy.

393

394

395 References

- 396 1. Vos T, Allen C, Arora M, Barber RM, Bhutta ZA, Brown A, et al. Global, regional, and national
397 incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a
398 systematic analysis for the Global Burden of Disease Study 2015. *The Lancet*. 2016 Oct
399 8;388(10053):1545–602.
- 400 2. Rasooly RS, Akolkar B, Spain LM, Guill MH, Del Vecchio CT, Carroll LE. The National Institute of
401 Diabetes and Digestive and Kidney Diseases Central Repositories: A Valuable Resource for
402 Nephrology Research. *Clin J Am Soc Nephrol*. 2015 Apr 7;10(4):710–5.
- 403 3. Deshpande AD, Harris-Hayes M, Schootman M. Epidemiology of Diabetes and Diabetes-Related
404 Complications. *Phys Ther*. 2008 Nov;88(11):1254–64.
- 405 4. Bin Rakhis SA, AlDuwayhis NM, Aleid N, AlBarrak AN, Aloraini AA. Glycemic Control for Type 2
406 Diabetes Mellitus Patients: A Systematic Review. *Cureus*. 14(6):e26180.
- 407 5. Tfayli H, Arslanian S. Pathophysiology of type 2 diabetes mellitus in youth: the evolving
408 chameleon. *Arq Bras Endocrinol Metabol*. 2009 Mar;53(2):165–74.
- 409 6. Home, Resources, diabetes L with, Acknowledgement, FAQs, Contact, et al. IDF Diabetes Atlas
410 2021 | IDF Diabetes Atlas [Internet]. [cited 2023 Jun 19]. Available from:
411 <https://diabetesatlas.org/atlas/tenth-edition/>
- 412 7. Atun R, Gale EAM. The challenge of diabetes in sub-Saharan Africa. *The Lancet Diabetes &*
413 *Endocrinology*. 2015 Sep 1;3(9):675–7.
- 414 8. Gill G. Diabetes in Africa - Puzzles and challenges. *Indian J Endocrinol Metab*. 2014;18(3):249–51.
- 415 9. Sandholzer-Yilmaz AS, Kroeber ES, Ayele W, Frese T, Kantelhardt EJ, Unverzagt S. Randomised
416 controlled trials on prevention, diagnosis and treatment of diabetes in African countries: a
417 systematic review. *BMJ Open*. 2022 May 10;12(5):e050021.
- 418 10. Bekele H, Asefa A, Getachew B, Belete AM. Barriers and Strategies to Lifestyle and Dietary
419 Pattern Interventions for Prevention and Management of TYPE-2 Diabetes in Africa, Systematic
420 Review. *J Diabetes Res*. 2020;2020:7948712.
- 421 11. Raveendran AV, Chacko EC, Pappachan JM. Non-pharmacological Treatment Options in the
422 Management of Diabetes Mellitus. *Eur Endocrinol*. 2018 Sep;14(2):31–9.

- 423 12. Prenissl J, Jaacks LM, Mohan V, Manne-Goehler J, Davies JI, Awasthi A, et al. Variation in health
424 system performance for managing diabetes among states in India: a cross-sectional study of
425 individuals aged 15 to 49 years. *BMC Medicine*. 2019 May 13;17(1):92.
- 426 13. Idrees T, Castro-Revoredo IA, Migdal AL, Moreno EM, Umpierrez GE. Update on the
427 management of diabetes in long-term care facilities. *BMJ Open Diabetes Res Care*. 2022
428 Jul;10(4):e002705.
- 429 14. World Health Organization. Monitoring the building blocks of health systems: a handbook of
430 indicators and their measurement strategies [Internet]. Geneva: World Health Organization;
431 2010 [cited 2023 Mar 16]. Available from: <https://apps.who.int/iris/handle/10665/258734>
- 432 15. Atun R, Davies JI, Gal EAM, Bärnighausen T, Beran D. Diabetes in sub-Saharan Africa: from
433 clinical care to health policy. 2017;5.
- 434 16. Timpel P, Harst L, Reifegerste D, Weihrauch-Blüher S, Schwarz PEH. What should governments
435 be doing to prevent diabetes throughout the life course? *Diabetologia*. 2019 Oct 1;62(10):1842–
436 53.
- 437 17. Nuche-Berenguer B, Kupfer LE. Readiness of Sub-Saharan Africa Healthcare Systems for the New
438 Pandemic, Diabetes: A Systematic Review. *Journal of Diabetes Research*. 2018 Feb 18;2018:1–
439 12.
- 440 18. Witter S, Palmer N, Balabanova D, Mounier-Jack S, Martineau T, Klicpera A, et al. Health system
441 strengthening—Reflections on its meaning, assessment, and our state of knowledge. *The*
442 *International Journal of Health Planning and Management*. 2019;34(4):e1980–9.
- 443 19. Byiringiro S, Ogungbe O, Commodore-Mensah Y, Adeleye K, Sarfo FS, Himmelfarb CR. Health
444 systems interventions for hypertension management and associated outcomes in Sub-Saharan
445 Africa: A systematic review. *PLOS Glob Public Health*. 2023;3(6):e0001794.
- 446 20. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020
447 statement: an updated guideline for reporting systematic reviews. *Systematic Reviews*. 2021
448 Mar 29;10(1):89.
- 449 21. Linné Y, Barkeling B, Rössner S. Natural course of gestational diabetes mellitus: long term follow
450 up of women in the SPAWN study. *BJOG*. 2002 Nov;109(11):1227–31.
- 451 22. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for
452 systematic reviews. *Systematic Reviews*. 2016 Dec 5;5(1):210.
- 453 23. Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane
454 Collaboration’s tool for assessing risk of bias in randomised trials. *BMJ*. 2011 Oct 18;343:d5928.
- 455 24. Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3.
456 Rating the quality of evidence. *J Clin Epidemiol*. 2011 Apr;64(4):401–6.

457

458

459 **Supporting Information**

460 **S1 Checklist. Prisma-P 2015 checklist**

461 (DOCX)

462 **S2 Table. Search strategy for PubMed**

463 (DOCX)

464 **S2 Fig. Study selection flow chart**

465 (DOCX)

466 **S3 Fig. PRISMA flow chart**

467 (DOCX)

468 **S3 Table. Data extraction Form**

469 (DOCX)

470 **S4 Fig. Cochrane Risk of Bias Tool**

471 (PDF)

472 **S5 Fig. The Grading of Recommendations, Assessment,**

473 **Development, and Evaluation (GRADE) Assessment Tool**

474 (PDF)